Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

DiaSorin SpA (34D)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
86.460 +0.280    +0.32%
02:02:32 - Closed. Currency in EUR ( Disclaimer )
Type:  Equity
Market:  Germany
ISIN:  IT0003492391 
S/N:  A0MTB2
  • Volume: 0
  • Bid/Ask: 90.060 / 91.060
  • Day's Range: 86.460 - 86.460
Diasorin 86.460 +0.280 +0.32%

DiaSorin SpA Company Profile

 
Get an in-depth profile of DiaSorin SpA, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryHealthcare Equipment & Supplies
SectorHealthcare
Employees

3278

Equity Type

ORD

DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS. It also offers molecular diagnostics platforms comprising of LIAISON NES, a new molecular platform to address the growing diagnostic decentralization trend; the ARIES and ARIES M1 systems; LIAISON MDX, a thermocycler with two consumable disc options; LIAISON MDX Plus; MAGPIX System; Luminex 100/200 System; VERIGENE System; and the LIAISON PLEX System. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.

Contact Information

Address Via Crescentino
Saluggia, 13040
Italy
Phone 39 01 614871
Fax 39 01 61 48 7628
Web diasoringroup.com/en

Top Executives

Name Age Since Title
Chen Menachem Even 60 2007 Chief Commercial Officer, Senior Corporate VP of Commercial Operations & Executive Director
Roberta Somati 54 2013 Independent Non-Executive Director
Fiorella Altruda 71 2016 Independent Director
Francesca Pasinelli 63 2016 Independent Director
Monica Tardivo 53 2016 Independent Director
Ottavia Alfano 52 2013 Statutory Auditor
Stefano Altara 56 2014 Non-Executive Director
Carlo Rosa 57 2006 CEO, GM & Executive Director
Francesco Moscetti 72 2007 Independent Non-Executive Director
Tullia Todros 75 2016 Independent Director
Michele Denegri 54 2007 Non-Executive Chairman
Monica Mannino 54 2016 Chairman of Board of Statutory Auditors
Matteo Michele Sutera 42 2019 Statutory Auditor
Diego Pistone 73 2022 Non-Executive Director
Giovanna Pacchiana Parravicini 54 2022 Independent Non-Executive Director
Luca Melindo 53 2019 Non-Executive Director
Andre-Michel Ballester 65 2022 Lead Independent Non-Executive Director
Giancarlo Boschetti 84 2016 Non-Executive Non-Independent Deputy Chairman
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

DIAS Comments

Write your thoughts about DiaSorin SpA
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Alessandro To
Alessandro To Apr 13, 2023 12:38AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
E comunwue oggi incremento . Bilanci dal 2020 raddoppiati.
Reply
0 0
Report
Tobias Raeder
Tobias Raeder Jun 02, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Che successe, mentre il resto sale?
Reply
1 0
Report
Tobias Raeder
Tobias Raeder Jun 02, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
superata la curva alta di Bollinger,  punta a 160 ?
Reply
2 0
Report
Robin Clerici
Robin Clerici Jun 02, 2021 10:28AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Tobias Raeder well said! It did it now
Reply
1 0
Report
Jhon Lucy
Jhon Lucy May 26, 2020 10:25AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Overrated company, in my opinion you can sell Short Diasorin capitalization 11 billion euros Profits 175 million euros Turnover 800 million ISIN IT0003492391 diasorin
Reply
2 7
Report
Saverio Daquino
Saverio Daquino May 25, 2020 2:01PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
short!!
Reply
1 8
Report
giulio corsi
giucor Apr 25, 2020 11:48AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
alla faccia del fattoquotidiano che oggi ha provato a dare un'altra spallata a questo gioiello... Coronavirus: da Fda via libera a test sierologico DiaSorin L'autorizzazione per analisi validata al San Matteo di Pavia (ANSA) - ROMA, 25 APR - DiaSorin annuncia di aver ricevuto l'Emergency Use Authorization (EUA) dalla Food and Drug Administration americana per il test LIAISON  SARS-CoV-2 S1/S2 IgG. Si tratta del nuovo test sierologico validato presso il Policlinico San Matteo a Pavia, uno dei centri di riferimento nazionali per la pandemia da COVID-19.
Reply
3 3
Report
Sam Lloyd
Sam Lloyd Mar 20, 2020 3:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
DIASORIN COVID fast test has been approved by FDA
Reply
9 0
Report
luca cas
luca cas Mar 20, 2020 3:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
nice news, not sure why is going down anyway
Reply
0 0
Report
Roby Carati
Roby Carati Mar 20, 2020 3:29AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
When??????
Reply
0 0
Report
Dario Fazio
Dario Fazio Mar 13, 2020 5:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
USA: Dow e NASDAQ han chiuso a +10%. Lunedì si parte da 120.10€. Buon weekend
Reply
2 1
Report
Captain USD
Captain USD Mar 13, 2020 5:28PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
E invece... 109.90€ :D
Reply
1 0
Report
Enea Caccamese
Enea Caccamese Mar 13, 2020 11:26AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
DiaSorin’s test could be ready within six weeks for consideration by the U.S. Food and Drug Administration, and the QIAGEN test could be ready within 12 weeks for FDA consideration, according to HHS.
Reply
0 0
Report
Sam Lloyd
Sam Lloyd Mar 11, 2020 11:46AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They just announced a fast test for COVID-19, 60 minutes against some hours
Reply
2 0
Report
Scotti Davide
SDavide Feb 04, 2020 8:22PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
150€ during this year ?
Reply
2 1
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email